These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12617152)

  • 1. Residual risk of transfusion-transmitted diseases in Japan and pathogen inactivation.
    Satake M
    Vox Sang; 2002 Aug; 83 Suppl 1():277-9. PubMed ID: 12617152
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.
    Walsh GM; Shih AW; Solh Z; Golder M; Schubert P; Fearon M; Sheffield WP
    Transfus Med Rev; 2016 Apr; 30(2):53-68. PubMed ID: 26962008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen inactivation: mechanisms of action and in vitro efficacy of various agents.
    Dodd RY
    Vox Sang; 2002 Aug; 83 Suppl 1():267-70. PubMed ID: 12617150
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogen inactivation of platelet concentrates and fresh frozen plasma.
    Jackson JE
    Br J Biomed Sci; 2003; 60(4):227-32. PubMed ID: 14725341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward universal pathogen reduction of the blood supply (Conference Report, p. 3002).
    Marks P; Verdun N
    Transfusion; 2019 Sep; 59(9):3026-3028. PubMed ID: 31218709
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine.
    AuBuchon JP
    Vox Sang; 2002 Aug; 83 Suppl 1():271-5. PubMed ID: 12617151
    [No Abstract]   [Full Text] [Related]  

  • 9. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).
    Atreya C; Glynn S; Busch M; Kleinman S; Snyder E; Rutter S; AuBuchon J; Flegel W; Reeve D; Devine D; Cohn C; Custer B; Goodrich R; Benjamin RJ; Razatos A; Cancelas J; Wagner S; Maclean M; Gelderman M; Cap A; Ness P
    Transfusion; 2019 Sep; 59(9):3002-3025. PubMed ID: 31144334
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics of pathogen inactivation technology for platelet concentrates in Japan.
    Staginnus U; Corash L
    Int J Hematol; 2004 Nov; 80(4):317-24. PubMed ID: 15615255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of pathogen inactivation during an outbreak of the new strain of influenza (H1N1).
    Narimatsu H; Yuji K; Shimodaira S; Kami M
    Transfus Med Rev; 2010 Apr; 24(2):151-2. PubMed ID: 20303039
    [No Abstract]   [Full Text] [Related]  

  • 12. Transfusion. Blood cleansing deemed safe, but more donors required.
    AIDS Policy Law; 2002 Aug; 17(16):8. PubMed ID: 12236221
    [No Abstract]   [Full Text] [Related]  

  • 13. Research, monitoring, and policy issues related to emerging pathogens.
    Kleinman S
    Vox Sang; 2002 Aug; 83 Suppl 1():351-4. PubMed ID: 12617167
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality.
    Vamvakas EC; Blajchman MA
    Transfus Med Rev; 2010 Apr; 24(2):77-124. PubMed ID: 20303034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission of human herpesvirus 8 by blood transfusion.
    Moore PS; Chang Y; Jaffe HW
    N Engl J Med; 2007 Jan; 356(1):88; author reply 89. PubMed ID: 17205612
    [No Abstract]   [Full Text] [Related]  

  • 16. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
    Corash L
    Vox Sang; 2000; 78 Suppl 2():205-10. PubMed ID: 10938954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing the transmission of bloodborne pathogens in health care and public service settings.
    Can Commun Dis Rep; 1997 May; 23 Suppl 3():i-vii, 1-43, i-vii, 1-52. PubMed ID: 11195251
    [No Abstract]   [Full Text] [Related]  

  • 18. Selected epidemiological aspects of fresh whole blood application in the Polish Field Hospital in Afghanistan.
    Olszewski A; Korzeniewski K; Lass A
    Int Marit Health; 2014; 65(1):23-7. PubMed ID: 24677124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature.
    Lozano M; Cid J; Prowse C; McCullough J; Klein HG; Aubuchon JP
    Transfusion; 2015 Mar; 55(3):690. PubMed ID: 25677714
    [No Abstract]   [Full Text] [Related]  

  • 20. The continuing risk of transfusion-transmitted infections.
    Blajchman MA; Vamvakas EC
    N Engl J Med; 2006 Sep; 355(13):1303-5. PubMed ID: 17005947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.